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Abstract
Background Methotrexate is one the most commonly used systemic therapies for psoriasis. Despite its widespread
use in psoriasis therapy, dermatologists’ practice regarding the use of methotrexate has not been investigated on global
scale.
Objective To evaluate the real life use of methotrexate for psoriasis treatment in the dermatological community world-
wide.
Methods A questionnaire consisting of 41 questions was designed by the Psoriasis International Network (PIN). Ques-
tions focused on safety, dosing, administration, folic acid supplementation and combination therapy aspects of metho-
trexate use. The anonymous web-based survey was distributed to dermatologists by the national coordinators of PIN.
Results Between 2 April and 7 August 2012, 481 dermatologists from 63 countries completed the questionnaire. Most
respondents were from European and South American countries, whereas the response rate from Central America and
the Near East was lowest. The majority of responders were experienced dermatologists (86% had more than 5 years of
experience in psoriasis treatment). Starting and maintenance doses of 10 mg of methotrexate or lower were reported by
67% and 42% of respondents respectively. Thirty-eight per cent of respondents stop treatment at a cumulative dose of
2 g, whereas 36% did not consider cumulative dose important in this respect. The primary mode of administration was
oral, and the majority of respondents administer folic acid supplementation. Almost all respondents monitored full blood
count, liver and renal function tests, whereas procollagen 3 amino terminal peptide measurement and transient elastog-
raphy is used by only a minority of dermatologists. There were signiﬁcant differences concerning the doses, routes of
administration and safety monitoring among the clinical practices in different geographical locations.
Conclusion Current clinical practice of methotrexate use in psoriasis is not uniform, depends on geographical location,
and is not in full agreement with clinical guidelines.
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Introduction
Psoriasis is a common, chronic, multifactorial, T-cell-mediated
inflammatory disease that affects 2–3% of the population.1,2
Methotrexate is an effective, commonly used systemic therapy
for moderate-to-severe psoriasis.3,4 Despite methotrexate having
been used for the treatment of psoriasis for more than 50 years,
regimens for use are not uniform in clinical practice. This can be
primarily attributed to the fact that methotrexate treatment has
developed without randomized clinical trials and uniform rec-
ommendations on how the drug should be used were lacking.
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This has led to the development of several dosing, scheduling,
safety monitoring and folic acid supplementation approaches.5,6
Recently, data accumulating from a few randomized trials have
led to the development of more consistent clinical recommenda-
tions.7,8 It is not known, however, how these recommendations
are translated into current dermatological practice. Whilst it
seems reasonable that differences in the characteristics of derma-
tologists (e.g. age, gender, experience) may contribute to differ-
ent treatment regimens, this has not been scientifically
investigated regarding methotrexate use in psoriasis. Further-
more, although there are anecdotal reports on the differences in
use of methotrexate in different geographical regions,9 no study
has been performed yet to identify these disparities.
Materials and methods
A questionnaire consisting of 41 questions was designed by the
board members of the Psoriasis International Network (PIN), a
network of psoriasis professionals and patient representatives
from 95 countries. Participants were asked to specify their age,
how experienced they were in the treatment of psoriasis, and
whether their practice was public hospital or private/office
based, or both. Questions focused on the dermatologist’s current
practice regarding pretreatment screening tests, safety monitor-
ing, dosing, drug administration, folic acid supplementation,
efficacy assessment and combination therapy aspects of metho-
trexate use. The anonymous web-based survey was distributed to
dermatologists by the national coordinators of PIN. The ques-
tionnaire can be viewed online following this link.
Statistical analysis was carried out using SPSS 15.0 statistical pro-
gram. Pearson chi-squared, paired t-test test were used. P values
of less than 0.05 were considered statistically significant.
Results
Between 2 April and 7 August 2012, 481 dermatologists from 63
countries completed the questionnaire. The questionnaires were
for the most part completed in their entirety; the response rate
Table 1 Baseline characteristics of survey respondents (N = 481)
Characteristics n (%)
Sex
Female 240 (49.9)
Male 241 (50.1)
Age
Mean overall (SD) 48.3 (10.7)
27–40 years 134 (27.8)
41–55 years 207 (43.0)
56–80 years 137 (28.5)
Missing 3 (0.7)
Years of experience in psoriasis treatment
Maximum 5 years 68 (14.1)
6–10 years 85 (17.7)
More than 10 years 326 (67.8)
Missing 2 (0.4)
Average weekly number of psoriasis patients consulted
0–5 120 (24.9)
6–10 133 (27.6)
11–20 117 (24.3)
21–50 86 (17.9)
>50 25 (5.2)
Region of practice
Africa 37 (7.7)
Near East 34 (7.1)
Europe 183 (38.0)
Asia 54 (11.1)
North America 37 (7.7)
Central America 24 (5.0)
South America 109 (22.7)
Missing or not included 3 (0.7)
Countries with at least ﬁve respondent
Algeria 10
Argentina 38
Brazil 13
Canada 27
Chile 11
Colombia 16
Costa Rica 11
Egypt 16
France 34
Georgia 12
Honduras 7
Hungary 17
India 20
Iran 8
Israel 9
Italy 9
Korea, South 5
Lebanon 6
Mexico 11
Palestine 5
Table 1 Continued
Characteristics n (%)
Peru 9
Portugal 5
Saudi Arabia 5
Slovenia 7
Spain 38
Taiwan (Republic of China) 17
Tunisia 5
Turkey 9
Ukraine 5
United Kingdom 24
United States of America 10
Venezuela 6
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to each question was over 98% (Table 1). Most respondents
were from European and South American countries (number of
respondent n = 183 and 109 respectively). The number of
responses received from other regions were comparable (Africa
n = 37; Near East n = 34; Asia n = 54; North America n = 37
and Central America n = 24). The following participating coun-
Table 2 Relationships of recommended methotrexate and folic acid doses with gender, age, clinical experience, geographical location
and methotrexate dose increase habit of the dermatologist
Week 1 Week 4 Maintenance Maximum Cumulative
MTX dose (g)
Folic acid weekly
dose (mg)
Weekly MTX dose (mg)
Total 9.7  5.1 12.9  4.6 12.3  4.5 22.1  5.3 2.5  1.1 16.8  11.7
Gender
Female 9.1  5.1 12.4  4.5 12.2  4.5 21.4  5.4 2.5  1.1 16.8  11.7
Male 10.3  5.0* 13.4  4.6* 12.4  4.6 22.8  5.2* 2.5  1.1 16.9  11.7
Age
28–40 years old 9.2  4.6 12.5  4.6 12.2  4.8 21.5  5.3* 2.3  0.9* 17.6  11.7
41–55 years old 10.0  4.8 13.0  4.4 12.5  4.5 21.9  4.8* 2.5  1.1 17.0  11.3
56–80 years old 9.9  5.9 13.3  4.7 12.2  4.3 23.2  5.9 2.7  1.2 16.0  12.2
Experience
<5 years of experience 9.3  4.7 12.1  4.2 11.4  4.7 21.0  5.1 2.4  1.1 18.7  12.9
6–10 years of experience 9.8  4.7 12.6  4.9 12.4  5.0 21.6  5.4 2.4  1.1 18.8  11.5
>10 years of experience 9.8  5.2 13.2  4.5 12.5  4.4 22.5  5.3* 2.6  1.1 16.0  11.4*
Location
Africa 13.4  5.2† 15.3  5.3† 12.8  5.2‡ 23.6  4.2‡ 2.0  0.6 22.2  9.9†
Near East 8.2  4.7‡,† 13.4  4.3† 12.4  4.6‡,† 22.4  4.1‡ 2.8  1.3‡,† 19.1  11.8
Europe 9.0  5.1‡,† 12.8  4.2‡,† 13.1  4.0‡,† 22.8  4.1‡ 2.7  1.2‡,† 14.8  11.4‡
Asia 8.6  4.6‡,† 11.3  4.2‡ 9.3  4.1† 18.2  5.8† 1.9  0.7 20.9  11.7†
North America 8.5  4.7‡,† 12.9  3.6‡ 14.7  3.4‡ 24.1  5.1‡ 3.0  1.1‡,† 16.1  11.8‡
Central America 10.5  5.2‡ 11.8  6.4‡ 10.5  5.5† 20.6  6.0† 2.4  1.2 21.6  13.0†
South America 10.9  4.7‡ 13.2  4.7‡,† 11.9  4.5‡,† 21.8  6.4‡,† 2.5  1.0‡,† 15.2  11.1‡
Dose increase practice
Never or rarely (n = 156) 11.5  5.8 14.2  5.2 12.1  5.3 20.7  5.6 2.4  1.1 17.3  11.4
Sometimes (n = 128) 9.4  4.6* 12.8  4.2* 12.1  4.4 22.1  5.0* 2.6  1.2 16.9  11.6
Often or always (n = 197) 8.5  4.3* 12.0  3.9* 12.7  3.9 23.2  5.1* 2.6  1.0 16.4  12.0
Gender: * P < 0.05 compared to females.
Age:
• Maximum weekly dose: *P < 0.05 compared to 56-80 years old.
• Cumulative dose: *P < 0.05 compared to 56-80 years old.
Experience:
• Maximum weekly dose: *P < 0.05 compared to <5 years of experience.
• Folic acid weekly dose: *P < 0.05 compared to 6–10 years of experience.
Location:
• Week 1 dose: ‡P < 0.05 compared to Africa, †P < 0.05 compared to South America.
• Week 4 dose: ‡P < 0.05 compared to Africa, †P < 0.05 compared to Asia.
• Maintenance dose: ‡P < 0.05 compared to Asia, †P < 0.05 compared to North America.
• Maximum weekly dose: ‡P < 0.05 compared to Asia, †P < 0.05 compared to North America.
• Cumulative dose: ǂP < 0.05 compared to Africa, †P < 0.05 compared to Asia.
• Folic acid weekly dose: ‡P < 0.05 compared to Africa, †P < 0.05 compared to Europe.
Dose increase practice:
• Week 1 dose: *P < 0.05 compared to Never or rarely.
• Week 4 dose: *P < 0.05 compared to Never or rarely.
• Maximum weekly dose: *P < 0.05 compared to Never or rarely.
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tries were considered as Near East: Iran, Israel, Lebanon, Kuwait,
Palestine and Saudi Arabia. The countries with the most partici-
pating dermatologists were Argentina, Spain and France
(n = 38, 38 and 34, respectively; for the list of countries with at
least five respondents, please see Table 1). As the response rate
from Australia and New Zealand was very low (one respondent
from each country), we did not include these two countries in
our subanalysis of geographical regions. The female-to-male
ratio was equal (240 vs. 241), and the majority of respondents
were middle aged, experienced dermatologists (mean age was
48.3 years, 86% had more than 5 years and 68% had more than
10 years of experience in psoriasis treatment). Male respondents
were somewhat older and more experienced than female respon-
dents (data not shown). Most dermatologists saw less than 20
psoriasis patients weekly.
Methotrexate dosing and administration
The most frequent starting dose of methotrexate was 7.5 mg
(n = 131, 27%), whereas 15 and 5 mg were the second and third
most frequently used doses (n = 100, 21% and n = 94, 20%,
respectively). Doses lower than or equal to 10 mg were recom-
mended by two-thirds of the respondent dermatologists
(n = 324, 67.4%). The mean starting dose was 9.7  5.1 mg
(Table 2). Respondents reported the use of increasing doses at
the second, third and fourth week of methotrexate therapy, the
mean doses being 11.7  4.5, 12.6  4.4 and 12.9  4.6 mg
respectively. At the second, third and fourth visits, 15 mg was
the most frequently recommended dose (n = 152, 31.6%,
n = 174, 36.2% and n = 191, 39.7% respectively). More than a
third of the respondents (n = 188, 39.1%) recommend a maxi-
mum dose of 10 mg at week 4.
We were interested to learn how frequently respondents
applied a test dose of methotrexate. We considered the first week
dose to be a test dose, if it was not more than 7.5 mg and the
dose was increased by a minimum of 5 mg at the next visit.
Using these criteria, 102 (21.2%) dermatologists used a test dose
strategy (data not shown). The mean methotrexate maintenance
dose (12.3  4.5 mg) was practically same as the week 4 dose,
and a large proportion of dermatologists (n = 204, 42.4%) pre-
scribe weekly doses of methotrexate at 10 mg or lower for treat-
ment maintenance. The mean maximum weekly dose was
22.1  5.3 mg. Again, a significant proportion of respondents
were cautious regarding the recommended highest doses: in 103
cases (21.5%) the maximum dose prescribed did not exceed
15 mg.
Concerning the maximum cumulative dose, it should be
noted that a significant number of dermatologists (n = 187,
38.9%) do not consider cumulative dose an important factor in
treatment continuation. Among those who provided a numerical
maximum cumulative dose, answers were almost equally distrib-
uted between 1.5 g (n = 86, 29.5%), 2.0 g (n = 82, 28.1%) and
3.0 g (n = 87, 29.8%), whereas 5 g doses were used by fewer
respondents (n = 34, 11.6%). The mean maximum cumulative
dose was 2.5  1.1 mg.
Female dermatologists were found to be more conservative
than males in their starting doses, with significantly lower doses:
9.1  5.1 mg vs. 10.3  5.0 mg at week 1 and 12.4  4.5 mg
vs. 13.4  4.6 mg at week 4 respectively) (Table 2. In contrast,
there was no difference in the recommended maintenance doses
between female and male respondents (12.2  4.5 and
12.4  4.6 mg respectively). While female dermatologists prefer
to apply lower maximum methotrexate doses (21.4  5.4 and
22.8  5.2 mg, females and males, respectively), there is no gen-
der difference in the cumulative methotrexate dose (2.5  1.1
and 2.5  1.1 g). The age and clinical experience of the derma-
tologists did not influence the recommended starting and main-
tenance doses of methotrexate doses: week 1, week 4 and
maintenance doses were not significantly different between the
groups of 28–40 years old, 41–55 years old and 56–80 years old
dermatologists, and the same applied to dermatologists with less
than 5 years’ experience, 6–10 years’ experience and more than
10 years’ experience in psoriasis treatment. In contrast, older
and more experienced dermatologists tended to use higher max-
imum weekly and cumulative methotrexate doses (for values
and significance see Table 2).
Interestingly, when the methotrexate dosing patterns in differ-
ent geographical locations were analysed, relatively large differ-
ences were found. The starting (week 1) methotrexate dose was
significantly higher in African countries (13.4  5.2 mg) than
in any other region. Dermatologists recommended rather
conservative week 1 doses in the Near East (8.2  4.7 mg),
Table 3 Primary mode of methotrexate administration in different
geographical locations
Oral Intramuscular Subcutaneous
Total (n = 481) 423 (87.9) 35 (7.3) 21 (4.4)
Gender
Female (n = 240) 216 (90.0) 14 (5.8) 10 (4.2)
Male (n = 241) 209 (86.7) 21 (8.7) 11 (4.6)
Location
Africa (n = 37) 24 (64.9) 13 (35.1) 0 (0.0)
Near East (n = 34) 28 (82.4) 6 (17.6) 0 (0.0)
Europe (n = 184) 157 (85.8) 9 (4.9) 18 (9.8)
Asia (n = 54) 52 (96.3) 2 (3.7) 0 (0.0)
North America
(n = 37)
37 (100.0) 0 (0.0) 0 (0.0)
Central America
(n = 24)
23 (95.8) 1 (4.2) 0 (0.0)
South America
(n = 109)
102 (93.6) 4 (3.7) 3 (2.8)
Values within parenthesis are expressed in percentage.
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North America (8.5  4.7 mg), Asia (8.6  4.6 mg) and Eur-
ope (9.0  5.1 mg), whereas respondents from Central and
South America generally use somewhat higher starting doses
(10.5  5.2 and 10.9  4.7 mg respectively). At the 4th week,
African dermatologists continue to be using the highest weekly
doses (15.3  5.3 mg), whereas the mean dose in Asia
(11.3  4.2 mg) is significantly lower than in most other
regions. The dosing pattern seems to change considerably during
the maintenance period, dermatologists in North America
recommending significantly higher maintenance and maximum
weekly doses (14.7  3.4 and 24.1  5.1 mg respectively) than
colleagues in most other geographical regions. In Asia, mean
maintenance and maximum doses (9.3  4.1 and 18.2  5.8 mg
respectively) are significantly lower than in any other region,
except for Central America. The highest and lowest cumulative
doses – calculated as the weekly maintenance dose multiplied by
the length of treatment (in weeks) – were reported in regions
with the highest and lowest maintenance doses, namely North
America and Asia (3.0  1.1 and 1.9  0.7 g respectively). It is,
however, somewhat surprising that the cumulative dose reported
by African dermatologists (2.0  0.6 g) is the second lowest
value. Thus, it appears that while the starting doses are high in
Africa, dermatologists tend to continue methotrexate treatment
for shorter periods than in other geographical regions.
We next analysed the relationship between the applied metho-
trexate doses and the dermatologists’ tendency to increase the
dose in case of non-satisfactory clinical improvement. Although
a large proportion of dermatologists (n = 197, 41.0%) always or
frequently (in more than 75% of cases) increase the dose in case
of inadequate therapeutic response, a significant portion
(n = 156, 32.4%) reported to either never or rarely do so in
patients with inadequate response. Interestingly, those who
never or rarely increase the dose prescribe significantly higher
first and fourth week doses of methotrexate than those who are
more likely to raise the dose (Table 2). On the other hand, while
there was no difference in the recommended maintenance and
cumulative doses between the groups, the maximum doses were
significantly lower among those who generally do not increase
the methotrexate dose in case of suboptimal therapeutic result
(Table 2).
Methotrexate administration
Most of the participating dermatologists (n = 423, 87.9%) pri-
marily prescribe oral methotrexate (Table 3); intramuscular and
subcutaneous administration is used considerably less frequently
(n = 35, 7.3% and n = 21, 4.4% respectively). Whilst the choice
of primary mode of methotrexate administration is not influ-
enced by the gender of the prescribing dermatologist, it is heavily
dependent on the geographical location. More than one-third of
African dermatologists (n = 13, 35.1%) principally prescribe
methotrexate in the form of intramuscular injection, whereas
subcutaneous use is almost exclusively limited to European
countries. A relatively small portion of respondents switch from
oral to intramuscular or subcutaneous administration always or
frequently (in more than 75% of cases) in case of inadequate
therapeutic response (n = 100, 20.8%) or gastrointestinal side
effects (n = 155, 32.2%). A number of respondents never or
rarely consider transitioning from oral to injectable methotrex-
ate (because of inadequate efficacy (n = 268, 55.7%) or gastroin-
testinal adverse events (n = 222, 46.2%).
Folic acid supplementation
Most of the participating dermatologists (n = 392, 81.5%) pre-
scribe folic acid supplementation during methotrexate treatment
in more than 75% of the cases (data not shown). On the other
hand, only 7 (1.5%) and 30 (6.2%) respondents reported that
Figure 1 Folic acid and methotrexate
weekly maintenance doses recommended
by the respondent dermatologist (n = 481).
Each dot represents one respondent. No
correlation was observed between the
applied weekly methotrexate and
recommended weekly folic acid doses.
© 2014 European Academy of Dermatology and VenereologyJEADV 2015, 29, 224–231
228 Gyulai et al.
they never or very rarely (in less than 25% of cases) supplement
methotrexate treatment with folic acid. The two most frequently
prescribed weekly doses were 30 mg and 5 mg (n = 97, 24.7%
and n = 84, 21.4% respectively). The mean weekly folic acid
dose was 16.8  11.7 mg, and it was not influenced significantly
by the gender, age and dose increasing habit of the dermatologist
(Table 2). On the other hand, physicians with less than 10 years
of experience in psoriasis treatment tended to recommend
higher doses than more experienced colleagues. Similarly,
geographical location of the respondent significantly influenced
the quantity of the recommended folic acid, as African
dermatologists reported at least 50% higher doses than Europe-
ans (22.2  9.9 and 14.8  11.4 mg respectively). No correla-
tion between the recommended folic acid dose and the
prescribed weekly maintenance dose of methotrexate was found
(Fig. 1).
Pretreatment work-up and safety monitoring
Complete blood count (CBC) and liver function tests (LFT)
were recommended by almost all participants before prescribing
methotrexate, while somewhat fewer, but still a significant por-
tion of dermatologists recommend renal function tests (RFT)
(Table 4). Hepatitis B and C serology tests are recommended by
approximately two-thirds of the respondents. While chest X-ray
films are used for tuberculosis screening relatively frequently
Table 5 Frequency of investigations recommended by respondent dermatologists in different geographical regions before methotrexate
therapy and for the monitoring of long-term liver toxicity during methotrexate treatment
Africa Near East Europe Asia North America Central America South America
Predose workup
CBC 36 (97.3) 33 (97.1) 180 (98.4) 54 (100.0) 37 (100.0) 24 (100.0) 108 (99.1)
Liver function tests 36 (97.3) 33 (97.1) 181 (98.9 54 (100.0) 37 (100.0) 23 (95.8) 109 (100.0)
Renal function tests 29 (78.4) 28 (82.4) 163 (89.1) 44 (81.5) 34 (91.9) 18 (75.0) 99 (90.8)
Hepatitis B serology 20 (54.1) 16 (47.1) 139 (76.0) 35 (64.8) 22 (59.5) 8 (33.3) 73 (67.0)
Hepatitis C serology 21 (56.8) 16 (47.1) 137 (74.9) 29 (53.7) 21 (56.8) 8 (33.3) 70 (64.2)
Albumin level 13 (35.1) 14 (41.2) 92 (50.3) 17 (31.5) 14 (37.8) 7 (29.2) 46 (42.2)
Prothrombin level 4 (10.8) 3 (8.8) 25 (13.7) 4 (7.4) 3 (8.1) 5 (20.8) 33 (30.3)
HIV serology 13 (35.1) 5 (14.7) 94 (51.4) 18 (33.3) 11 (29.7) 6 (25.0) 66 (60.6)
Chest X-ray 13 (35.1) 9 (26.5) 86 (47.0) 28 (51.9) 14 (37.8) 6 (25.0) 58 (53.2)
Mantoux test 1 (2.7) 8 (23.5) 27 (14.8) 7 (13.0) 4 (10.8) 3 (12.5) 44 (40.4)
Quantiferon test 1 (2.7) 2 (5.9) 21 (11.5) 2 (3.7) 4 (10.8) 1 (4.2) 3 (2.8)
ANA screen 0 (0.0) 1 (2.9) 15 (8.2) 1 (1.9) 0 (0.0) 4 (16.7) 18 (16.5)
Procollagen 3 (8.1) 1 (2.9) 45 (24.6) 1 (1.9) 0 (0.0) 1 (4.2) 4 (3.7)
Transient elastography 1 (2.7) 1 (2.9) 13 (7.1) 0 (0.0) 1 (2.7) 1 (4.2) 2 (1.8)
Long-term liver toxicity workup
Transient elastography 2 (5.4) 7 (20.6) 57 (31.1) 4 (7.4) 9 (24.3) 2 (8.3) 11 (10.1)
Procollagen 13 (35.1) 7 (20.6) 85 (46.4) 6 (11.1) 0 (0.0) 2 (8.3) 12 (11.0)
Liver biopsy 6 (16.2) 14 (41.2) 13 (7.1) 9 (16.7) 13 (35.1) 4 (16.7) 23 (21.1)
Highest frequencies are marked with dark grey shading, whereas lowest frequencies are marked with white shading.
Values within parenthesis are expressed in percentage.
Table 4 Frequency of examinations recommended by respondent
dermatologists before and during methotrexate therapy of psoria-
sis
Pretreatment 1st
month
2nd–3rd
months
After 3
months
CBC 474 (98.5) 473 (98.3) 467 (97.1) 467 (97.1)
Liver function
tests
475 (98.8) 460 (95.6) 472 (98.1) 471 (97.9)
Renal function
tests
417 (86.7) 314 (65.0) 325 (67.6) 342 (71.1)
Hepatitis B
serology
314 (65.3) 20 (4.2) 11 (2.3) 10 (2.1)
Hepatitis C
serology
303 (63.0) 18 (3.7) 10 (2.1) 11 (2.3)
Albumin level 205 (42.6) 129 (26.8) 136 (28.3) 147 (30.6)
Prothrombin
level
77 (16.0) 68 (14.1) 65 (13.5) 73 (15.2)
HIV serology 213 (44.3) 13 (2.7) 5 (1.0) 5 (1.0)
Chest X-ray 214 (44.5) 25 (5.2) 27 (5.6) 28 (5.8)
Mantoux test 94 (19.5) 6 (1.2) 5 (1.0) 7 (1.5)
Quantiferon test 34 (7.1) 2 (0.4) 5 (1.0) 4 (0.8)
ANA screen 43 (8.9) 9 (1.9) 7 (1.5) 7 (1.5)
Procollagen 56 (11.6) 8 (1.7) 20 (4.2) 44 (9.1)
Transient
elastography
19 (4.0) 3 (0.6) 4 (0.8) 6 (1.2)
Values within parenthesis are expressed in percentage.
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(n = 214, 44.5%), Mantoux and interferon release tests are not
as widespread (n = 94, 19.5% and n = 34, 7.1% respectively).
Similarly, the use of procollagen 3 amino terminal peptide
(PIIIP) and transient elastography examinations, as well as anti-
nuclear antibody (ANA) determinations, is limited (n = 56,
11.6%; n = 19, 4.0%; n = 43, 8.9%, respectively). Almost half of
the dermatologists recommended HIV screening and albumin
level determination before starting methotrexate therapy
(n = 213, 44.3% and n = 205, 42.6% respectively). While the
frequency of dermatologists recommending CBC, LFT and RFT
continues to be high during subsequent visits, only a few partici-
pant order viral hepatitis and HIV serology, chest X-ray, Man-
toux test, interferon release assay or serum ANA titres. The
percentages of respondents performing serum albumin and pro-
thrombin level examinations on follow-up visits remained
almost constant (Table 4).
Next, we subdivided the workup results according to the geo-
graphical location of the respondent dermatologists (Table 5).
CBC, LFT and RFT were uniformly frequently recommended in
the pretreatment workup. Hepatitis B and C serologic tests are
part of routine examinations in Europe, as approximately three-
quarters of dermatologists perform the test; these tests are rarely
ordered in Central America (n = 8, 33.3% for both tests). Inter-
estingly, HIV testing, chest X-ray and Mantoux testing is most
frequently ordered in South America, whereas interferon release
assays, PIIIP measurement, and transient elastography examina-
tions are performed mostly in Europe. It is also somewhat sur-
prising that the use of ANA screening, PIIIP and transient
elastography was rarely reported from North America.
Regarding the long-term monitoring of liver toxicity, tran-
sient elastography and PIIIP examinations were most popular
among European dermatologists (n = 57, 31.1% and n = 85,
46.4%, respectively). Interestingly, while PIIIP determinations
are not performed in North America, liver biopsy is relatively
frequently recommended there and in the Near East (n = 14,
41.2% and n = 13, 35.1%, respectively). Liver biopsy is only
performed occasionally in Europe (n = 13, 7.1%).
Discussion
Although the number of respondents in this survey was high,
their geographical distribution was not uniform. As the idea of
this survey originated in Europe, it is not surprising that the con-
tribution from European countries was highest. While in other
regions the response rate was lower, we may still consider the
results to be representative for the given area. It is likely that der-
matologists with an interest in methotrexate treatment are prob-
ably overrepresented in this survey, and thus, the use of
methotrexate in the total dermatological community is perhaps
lower than calculated here. Nevertheless, despite all the draw-
backs of the online survey approach, our results are the first
to provide a global snapshot of methotrexate prescribing for
psoriasis.
Several of the survey results were surprising. Generally, meth-
otrexate doses were lower than those recommended by current
guidelines.7,8 Approximately two-thirds of the dermatologists
start with doses lower than or equal to 10 mg, and more than
40% of respondents prescribe 10 mg or lower doses for mainte-
nance treatment. Interestingly, female dermatologists were
found to be more conservative in choosing their starting dose;
however, their maintenance strategy did not differ from that of
male colleagues. A substantial portion of dermatologists (n =
187, 38.9%) do not consider cumulative dose an important fac-
tor in the decision of treatment continuation, suggesting that
new tools for hepatotoxicity monitoring may change our
approach to methotrexate treatment.
Perhaps the most interesting findings relate to the differ-
ences between geographical regions. It seems that the adminis-
tration schedules are quite diverse. In Africa dermatologists
start with high doses but maintenance doses are not as high in
some geographical regions, and they tend to continue metho-
trexate treatment for shorter periods of time. North American
based dermatologists recommend the highest maintenance and
maximum weekly doses, as well as the highest maximum
cumulative doses. The opposite occurs in Asia, where doses are
at least 25% lower in every category. This may perhaps be due
to a greater incidence of adverse effects in the Asian popula-
tion: according to a recent report, more than 50% of patients
treated with methotrexate in a psoriasis centre in Malaysia
developed deranged liver transaminases, and almost 10%
required MTX withdrawal due to hepatotoxicity.10 Conse-
quently, Asian-based dermatologists use increased caution
when prescribing methotrexate. Another important factor to
consider would be higher body mass index (BMI) in the USA
and Europe compared to Asia (the average male BMI in the
USA, France and Japan are 29, 25.55 and 23.7 respectively).
Moreover, regulatory differences may also affect clinical prac-
tice in different regions. In any case, these results indicate that
extrapolation of data from clinical trials performed in one geo-
graphical area to another carries significant risk. It is also inter-
esting to note that more than one-third of African
dermatologists principally prescribe intramuscular methotrex-
ate, whereas subcutaneous use is almost exclusively limited to
European countries.
According to our results, folic acid is generally prescribed by
dermatologists in association with methotrexate therapy; how-
ever, dosing and scheduling are far from being uniform, as
reported previously.11–13 Weekly doses of folic acid are not
dependent on the prescribed weekly maintenance dose of meth-
otrexate. On the other hand, geography is again an important
factor, as African dermatologists reported the use of significantly
higher doses than colleagues from other regions.
While there are some common themes in predosing and fol-
low-up workup examinations, such as liver and RFT and CBC,
there are major differences as well. The relatively high frequency
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of HIV testing, chest X-ray and Mantoux testing in Africa is
probably due to the high prevalence of HIV and tuberculosis in
this region. However, the use of interferon release assays, PIIIP
and transient elastography examinations is limited by cost. It is
also somewhat surprising that use of ANA screening, PIIIP and
transient elastography was practically unreported in North
America. Regarding the long-term monitoring of liver toxicity,
the use of transient elastography and PIIIP examinations in
Europe seem to provide enough data to avoid liver biopsy, as
suggested by a report from a recent consensus conference.14
Interestingly, in North America, liver biopsy is still relatively
frequently recommended.
According to our findings, the use of methotrexate in clinical
practice appears to differ substantially from guideline recom-
mendations in several aspects, particularly dosing. It should be
noted, however, that there is limited evidence from randomized
controlled trials regarding methotrexate dosing in psoriasis, and
evidence-based data is mostly derived from European and
North-American clinical trials. As this forms the foundation for
currently available guidelines, it is not surprising that European
and North-American survey respondents seem to be more com-
pliant with guidelines than dermatologists from other regions.
As referred to earlier, these deviations may stem from regulatory
variances, differences in the physiological aspects of the popula-
tions or simply prescribing tradition. Therefore, we suggest that
the aetiology of these geographical differences should be investi-
gated. There may be various underlying reasons, e.g. population
differences in liver enzyme function or weight. If, however, this
is not the case, the reason of deviation from the guidelines (e.g.
local regulations, common myths in the dermatologic commu-
nity, etc.) should be ascertained and corrected.
The results of this study are limited by several factors. Surveys
generally provide lower quality information; however, this is
usually balanced by the robustness of data due to the large sam-
ple size of the studied population. In addition, it is likely that
dermatologists with more experience in methotrexate therapy
are overrepresented in this study; therefore, the conclusions may
not necessarily reflect the clinical practice of the entire dermato-
logical community. Furthermore, the geographical distribution
of respondents was uneven, thus, some countries or continents
are underrepresented in the study.
In conclusion, while survey methodology might provide less
accurate data than other methods, our study provides substantial
new information regarding the use of methotrexate for psoriasis
treatment. There is a need to harmonize methotrexate use in
psoriasis, taking into account geographical and potential ethnic
differences in drug efficacy and safety.
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